Since launching in 2014, Thirona has made significant progress in leveraging artificial intelligence to deliver high-precision advanced lung image analysis and expertise-based services for MedTech, pharmaceutical and CRO companies. This year we received FDA approval for the latest iteration of our AI-based clinical software LungQ™ (v3.0.0.). Its new features which are essential for planning and performing minimally invasive localized treatments and lung cancer biopsies are now widely available for use in hospitals in the United States.  

To achieve our mission of advancing personalized and tailored approaches to lung disease treatment, we have always relied on the collaboration with our clinical expert partners. 

We are now proud to announce our Medical Advisory Board members, who are amongst the top global leaders in interventional pulmonology and bronchoscopy: 

• Prof. Dr. Dirk-Jan Slebos, MD​, University Medical Center Groningen, The Netherlands - Prof. Slebos, is Head of Pulmonary Medicine, and Tuberculosis at University Medical Center Groningen and Professor of Interventional Pulmonology. Specialized in interventional bronchoscopy, he is one of the pioneers of the minimally invasive endobronchial treatment for COPD patients with severe emphysema. His areas of interest include severe COPD, lung failure, benign and malignant central airway pathology, and innovative treatments for interventional bronchoscopy.​  

• Prof. Dr. Pallav Shah, Royal Brompton Hospital, United Kingdom​ - Dr. Shah is Professor of Respiratory Medicine at the National Heart & Lung Institute - Faculty of Medicine, and the lead clinician for lung cancer services at Royal Brompton Hospital and the Chelsea & Westminster Hospital. He is involved in the development of new bronchoscopic techniques for early detection and therapeutic interventions in lung cancer, using a combination of intra-operative imaging, novel devices and robotics to approach peripheral lung nodules. His current research interests also include the role of innovative treatments in COPD, from chronic bronchitis to emphysema, and airway diseases. ​ 

• Dr. Krish Bhadra​, CHI Memorial Hospital, United States​ - Dr. Bhadra leads Interventional Pulmonology clinic at CHI Memorial Medical, focusing on minimally-invasive procedures for treatment of lung and airway conditions, including lung cancer and severe emphysema. His interests include research, diagnostic and therapeutic interventions for thoracic oncology patients and benign lung disease. As a leading bronchoscopist in the United States, he utilizes cutting-edge technology to navigate the intricacies of the airway and lungs. Dr. Bhadra was the first in the world to use digital tomosynthesis. ​ 

With the support and expertise of the Advisory Board, we continue to leverage the latest domain knowledge and artificial intelligence technology to create positive impact. Working closely with medical experts to generate clinical evidence on improved outcomes and patient safety measures from the regulatory perspective remains critical in harnessing the full potential of AI. Together, we can contribute to improving the quality of patients’ lives and making the benefits of the technology reach patients worldwide.